EXCLUSIVE: TransCode's RNA Therapeutic TTX-MC138 Achieves 64% Stable Disease Rate Lasting Six Months In Phase 1a Trial; Reports Positive Safety And Disease Stabilization Data

뉴스 본문을 불러오고 있어요.

EXCLUSIVE: TransCode's RNA Therapeutic TTX-MC138 Achieves 64% Stable Disease Rate Lasting Six Months In Phase 1a Trial; Reports Positive Safety And Disease Stabilization Data | 웨이프 WAPE

EXCLUSIVE: TransCode's RNA Therapeutic TTX-MC138 Achieves 64% Stable Disease Rate Lasting Six Months In Phase 1a Trial; Reports Positive Safety And Disease Stabilization Data

기사 요약

관련 종목

댓글 —